Good to see Steve Gourlay posting yesterday that Sanofi has had good results in a phase 3 trial of one of the Principia molecules it purchased. This supports Dr Gourlay's credibility. At a recent ASX investor day he said Actinogen is a larger clinical and commercial opportunity than Principia which Sanofi bought for US 3.7b with phase 2 data.
